Abstracts

Cytochrome polymorphisms and the therapeutic response of cannabidiol in patients with drug-resistant epilepsy.

Abstract number : 1.395
Submission category : Camelice Poster
Year : 2021
Submission ID : 1886463
Source : www.aesnet.org
Presentation date : 12/4/2021 12:00:00 PM
Published date : Nov 22, 2021, 06:56 AM

Authors :
ALEXIA MONTES, MD - IMSS CMN XXI; IRIS ROMERO, DR - RESEARCHER, Unit of Medical Research in Neurological Diseases, Specialties hospital “Dr. Bernardo Sepúlveda”, XXI Century National Medical Center, Mexican Institute of Social Security, IMSS, IMSS CMN XXI; LUISA ROCHA, DR - RESEARCHER, Department of Pharmacology, Center for Research and Advanced Studies, South Headquarters, Center for Research and Advanced Studies, South Headquarters, Mexico City; DARIO MARES, DR - MEDICAL DOCTOR, Pediatric Neurology Service, Pediatric hospital, Century National Medical Center, Mexican Institute of Social Security, IMSS, IMSS CMN XXI; ARACELY REYES, DR - MEDICAL DOCTOR, Pediatric Neurology Service, Pediatric hospital, Century National Medical Center, Mexican Institute of Social Security, IMSS, IMSS CMN XXI; SANDRA OROZCO, DR - RESEARCHER, Unit of Medical Research in Neurological Diseases, Specialties hospital “Dr. Bernardo Sepúlveda”, XXI Century National Medical Center, Mexican Institute of Social Security, IMSS, IMSS CMN XXI

Rationale: In Mexico, 30% of epileptic patients are resistant to drug treatment. Given the low response to current anti-epileptic drugs (AEDs) for the control of drug-resistant epileptic seizures, the use of cannabidiol (CBD) is a current and real alternative that is already used in patients, although it is not in the basic treatment. This molecule is metabolized mainly by the cytochrome family (CYP). Knowledge of those CYP genetic variants that affect CBD metabolism may provide relevant information to the treating physician. Aim: To analyze the association between CYP polymorphisms and the therapeutic response to CBD in Mexican patients with drug-resistant epilepsy.

Methods: Retrospective, analytical and cross-sectional study of pediatric epilepsy patients of both sexes. Genomic DNA was obtained, and a massive genetic sequencing study was carried out to detect genetic variants in the genes belonging to CYPs. The OR statistic was determined to quantify the degree of risk (95% CI); additionally, it was performed with Fisher's exact test (p < 0.05) to know the statistical significance.
Camelice Poster